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TuberculosisThe number of multidrug-resistant tuberculosis patients is increasing each year in many
countries all around the globe. Malaysia has no exception in facing this burdensome health
problem. We aimed to investigate the factors that contribute to the occurrence of
multidrug-resistant tuberculosis among Malaysian tuberculosis patients. An unmatched
case-control studywas conducted among tuberculosis patientswho received antituberculo-
sis treatments from April 2013 until April 2014. Cases are those diagnosed as pulmonary
tuberculosis patients clinically, radiologically, and/or bacteriologically, and who were con-
firmed to be resistant to both isoniazid and rifampicin through drug-sensitivity testing. On
theotherhand,pulmonary tuberculosispatientswhoweresensitive toall first-lineantituber-
culosis drugs andwere treated during the same time period served as controls. A total of 150
tuberculosis patientswere studied, of which the susceptible caseswere 120. Factors found to
be significantly associatedwith the occurrence ofmultidrug-resistant tuberculosis are being
Indian or Chinese (odds ratio 3.17, 95% confidence interval 1.04–9.68; and odds ratio 6.23, 95%
confidence interval 2.24–17.35, respectively), unmarried (odds ratio 2.58, 95% confidence
interval 1.09–6.09), living in suburban areas (odds ratio 2.58, 95% confidence interval 1.08–
6.19), are noncompliant (odds ratio 4.50, 95% confidence interval 1.71–11.82), were treated
previously (odds ratio 8.91, 95% confidence interval 3.66–21.67), and showed positive sputum
smears at the 2nd (odds ratio 7.00, 95% confidence interval 2.46–19.89) and 6th months of
treatment (odds ratio 17.96, 95% confidence interval 3.51–91.99). Living in suburban areas,
positive sputum smears in the 2nd month of treatment, and was treated previously are fac-
tors that independently contribute to the occurrence of multidrug-resistant tuberculosis.
Those with positive smears in the second month of treatment, have a history of previous
treatment, and live in suburbanareasare found tohaveahigherprobabilityof becomingmul-
tidrug resistant. The results presented here may facilitate improvements in the screening
and detection process of drug-resistant patients in Malaysia in the future.
 2015 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Medicine,
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many people in the world, and until now, the formula or
recipe to eliminate the disease is still vague and has yet to
be found [1]. Recently, the world does not only have to face
higher numbers of new TB cases each year, but another chal-
lenge arises in the form of multidrug-resistant TB (MDR-TB).
This new development can shake the efforts done in tackling
and managing this disease. By definition, a TB patient is clas-
sified as MDR-TB if he or she shows resistance to two most
potent anti-TB drugs, namely, isoniazid and rifampicin, with
or without resistance to other first-line drugs [2]. According
to a recent report, an estimated 3.6% of new TB cases and
20.2% of those previously treated patients are MDR-TB glob-
ally in year 2012 [2].
Even though Malaysia is classified as an intermediate TB-
burden country and a low MDR-TB burden (0.3–1.3% of all
culture-positive TB patients were detected MDR-TB) by the
World Health Organization [3], yet we are surrounded by
countries with higher burdens of TB and high prevalence of
MDR-TB, for example, Myanmar and Indonesia. In year
2013, an estimated 22% and 13% of all TB patients in Myan-
mar and Indonesia were detected and notified to be MDR-
TB, respectively [2]. The influxes of foreign workers from
these countries, TB/human immunodeficiency virus (HIV)
coepidemic, and poor treatment to some extent are believed
to contribute to an increase in the incidence of TB and the
emergence of drug-resistant cases in Malaysia. Consequently,
TB has become the top leading cause of death among other
communicable diseases in Malaysia for 8 consecutive years
since 2006 until 2013 [4,5]. Even more alarming, since 2013,
we are seeing confirmed cases of extensively drug-resistant
TB being detected and started treatment in Malaysia [2]. This
rare type of multidrug-resistant patients (who are not only
resistant to isoniazid and rifampicin, but also to fluoro-
quinolones and at least one injectable second-line anti-TB
drugs) brings more challenges in tackling TB in Malaysia.
However, fortunately until now, no cases of totally drug-
resistant TB were reported in Malaysia.
In response to these data, several studies had been carried
out by previous researchers in some states in Malaysia to try
to look into the epidemiology of the disease, reasons for
patients defaulting treatment, evaluation of TB treatment
outcomes, as well as the prevalence of drug-resistant-TB
cases in Malaysia [6–8]. However, to the best of the authors’
knowledge, far too little attention has been paid to the cause
of patients’ resistance to the twomost potent anti-TB drugs in
Malaysia. Therefore, this present study aimed to determine
the factors that influence the occurrence of MDR-TB among
Malaysian TB patients. This study is expected to assist treat-
ment providers in Malaysia in designing the preventive
approach and in the detection of drug-resistant cases,
tailored to local circumstances. Previous international studies
have demonstrated a significant association between several
risk factors, such as history of previous TB treatment, HIV
positive, diabetes, smoking, treatment noncompliant, and
alcoholism, and MDR-TB [9–11].Ethical considerations
This study has received ethical approval from the Malaysian
Research & Ethics Committee, Ministry of Health Malaysia,
and is registered under the National Medical Research
Registry (NMRR-12-1218-12850). In addition, this study also
received approval from the Secretariat of Medical Research
& Innovation, Universiti Kebangsaan Malaysia Medical Cen-
tre. Clear explanations had been given to each participant at
the beginning of the study, and simultaneously, an informed
consent was obtained. Participants were recruited on a volun-
tary basis.
Study population and design
This recent study was carried out at the Institute of
Respiratory Medicine located in Jalan Pahang, Kuala Lumpur,
Malaysia. This government tertiary hospital was formerly
known as the National Tuberculosis Centre. We conducted
an unmatched case-control study among TB patients who
received anti-TB treatments from April 2013 until April 2014
at this health institute. Cases were purposively selected
among those who are clinically, radiologically, and/or bacteri-
ologically diagnosed as pulmonary TB patients; aged 18 years
old and above; have local citizenship; and were confirmed to
be resistant to both isoniazid and rifampicin through drug-
sensitivity testing. On the other hand, pulmonary TB patients
who fulfilled the mentioned criteria and were treated during
the same time period, but sensitive to all first-line anti-TB
drugs were randomly selected as controls.
Data collection
Data were obtained from both the patients’ medical records
and a set of pretested self-administered questionnaires. The
patients’ medical records were reviewed to obtain informa-
tion, such as age at diagnosis, gender, home address, type
of TB, drug and sensitivity test results, diabetic status, HIV
status, and sputum-smear status at three intervals (at diagno-
sis, 2nd month, and 6th month). On the other hand, the ques-
tionnaire was used to obtain information regarding their
marital status, occupation, ethnicity, education level, history
of imprisonment, exposure to other TB cases, adherence to
treatment, smoking history, alcohol intake, history of drug
abuse, and house characteristics. Household crowding was
categorized according to the definition of person per
bedroom. A household is classified as crowded if more than
two persons stay in the same bedroom [12]. The classification
of patients’ area of living, either urban or suburban, was car-
ried out by referring to the standardized definition by the
Department of Statistics Malaysia based on the Population
and Housing Census of 2010 [13]. The level of nicotine depen-
dency was measured using the Malay version of the Fager-
strom test for nicotine dependence adapted from a previous
study [14]. A passive smoker is defined as someone who is
reported to be regularly aware of seeing and smelling, or
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defined as missing more than 25% of treatments in a month
(i.e., missed more than 1-week injection [daily/intermittent],
or missed more than 1 week for collection of oral drugs)
(known as defaulters), or defaulting for more than 1 month
(known as abandoned treatment). The noncompliance group
is also included in the group of return-after-default patients [7].
Statistical analysis
Data were analyzed using SPSS software version 20.0 for Win-
dows (IBM Corporation, New York, United States). Descriptive
data are presented in the terms ofmean, median, frequencies,
percentage, or interquartile range. In the univariable analysis,
Pearson chi-square test or Fisher’s exact test was used in
analyzing the differences and associations between categori-
cal variables. Meanwhile, the differences and association
between continuous variables (age and duration of smoking)
were tested using Mann–Whitney U test. The nonparametric
tests were used whenever the variables were not normallyTable 1 – Sociodemographic characteristics of cases and control
Cases (n = 30) Controls (n = 120)
n % n %
Sex
Male 20 66.7 72 60.0
Female 10 33.3 48 40.0
Marital status
Single 21 70.0 57 47.5
Married 9 30.0 63 52.5
Occupation
Laborer 5 16.7 39 32.5
Unemployed 15 50.0 45 37.5
Nonlaborer 10 33.3 36 30.0
Ethnicity
Indian 6 20.0 13 10.8
Chinese 10 33.3 11 9.2
Malay 14 46.7 96 80.0
Education
Primary 4 13.3 13 10.8
Secondary 14 46.7 73 60.8
Tertiary 12 40.0 34 28.4
History of incarceration
Yes 3 10.0 12 10.0
No 27 90.0 108 90.0
Exposed to TB patients
Yes 4 13.3 25 20.8
No 26 86.7 95 79.2
Note: History of incarceration: history of imprisonment or drug-rehabilita
TB = tuberculosis.
a Pearson chi-square test was performed.
b Simple binary logistic regression was performed.distributed. Variables found to be statistically significant in
the univariable analysis were further analyzed using a
multiple binary logistic-regression analysis to determine the
factors that independently influence the occurrence of
MDR-TB. The level of significance was set to .05 at a 95% con-
fidence interval.
Results
A total of 51 clinically confirmed laboratory MDR-TB cases
were found in this center during the period of study. Out of
this number, 37.3% (n = 19) were non-Malaysian patients. For
the purpose of this study, all 32 local Malaysian patients
who were eligible for this study were purposively approached
to participate. Meanwhile, all of the non-Malaysian
multidrug-resistant cases were excluded from this study.
The response rate is 93.8% (two of the local multidrug-
resistant patients refused to take part due to other commit-
ments). At the end of this study, 30 local MDR-TB cases and
120 drug-susceptible controls were involved. The studieds.
Chi squarea p Crude odds ratiob (95% CI)
.45 .503 1.33 (.57–3.09)
Ref.
4.87 .031 2.58 (1.09–6.09)
Ref.
3.08 .230 .46 (.14–1.48)
1.20 (.48–2.99)
Ref.
15.24 .001 3.17 (1.04–9.68)
6.23 (2.24–17.35)
Ref.
2.03 .368 .87 (.24–3.19)
.54 (.23–1.29)
Ref.
.00 >.950 1.00 (.26–3.79)
Ref.
.87 .59 (.19–1.83)
.357 Ref.
tion inmates prior to tuberculosis diagnosis. CI = confidence interval;
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Kuala Lumpur, Malaysia for more than 10 years.
The median age of the cases is 47 years old, with a range
between 35 years old and 58 years old. Meanwhile, the med-
ian age for the controls is 36 years old with a range between
27 years old and 50 years old. Majority of the patients are
males (61.3%) and are still single (52%). It is also found that
73.3% (n = 110) of the patients are Malays.
As Table 1 shows, those who are single have three times
the possibility of developing MDR-TB compared to those
who are married (odds ratio [OR] 2.58, 95% confidence interval
[CI] 1.09–6.09). With regard to ethnicity, those who are Chi-
nese are found to be six times more likely to develop MDR-
TB compared to Malays (OR 6.23, 95% CI 2.24–17.35). On the
other hand, Indians are three times more likely to develop
MDR-TB as compared to Malays (OR 3.17, 95% CI 1.04–9.68).
Unfortunately, no significant relationship was seen between
other sociodemographic characteristics and the occurrence
of MDR-TB in this study.
Next, this study revealed significant relationships between
the patients’ living areas and diabetes, and the occurrence of
MDR-TB. As shown in Table 2, it is found that those who live
in suburban areas are three times more likely to develop
MDR-TB as compared to those who live in urban areas
(OR = 2.58, 95% CI 1.08–6.19). Similarly, those who are
diabetic are two times more likely to develop MDR-TB as com-
pared to those without this metabolic disease (OR 2.44, 95% CI
1.02–5.83). However, this study failed to prove a significant
association between household crowding and HIV with
MDR-TB.
In the univariable analysis, it was also found that those
who are not in compliance with their treatment schedules
are five times more likely to develop MDR-TB compared to
those who religiously comply to their treatments (OR 4.50,
95% CI 1.71–11.82). On the other hand, patients with a pastTable 2 – Living and clinical characteristics of cases and control
Cases (n = 30) Controls (n = 120)
n % n %
Area of living
Urban 19 63.3 98 81.7
Suburban 11 36.7 22 18.3
Household crowding (person/room)c
Crowded 3 10.0 14 11.7
Not crowded 27 90.0 106 88.3
Diabetes
Yes 11 36.7 23 19.2
No 19 63.3 97 80.8
HIVc
Positive 3 10.0 17 14.2
Negative 27 90.0 103 85.8
Note: Statistically significant at p < .05. CI = confidence interval; HIV = hu
a Pearson chi-square test was performed.
b Simple binary logistic regression was performed.
c Fisher’s exact test was performed.history of TB treatment are nine times more likely to develop
MDR-TB as compared to newly diagnosed patients (OR 8.91,
95% CI 3.66–21.67) (Table 3).
Moreover, sputum-smear conversions at the 2nd and 6th
months of treatment are also found to be significantly
associated with the occurrence of MDR-TB. Based on the
results, those with positive sputum smears at the 2nd month
of treatment are seven times more likely to develop
MDR-TB as compared to those with negative sputum smears
(OR 7.00, 95% CI 2.46–19.89). Meanwhile, those with positive
sputum smears at the 6th month of treatment are 18 times
more likely to develop MDR-TB as compared to those with
negative sputum smears (OR 17.96, 95% CI 3.51–91.99)
(Table 3).
This study failed to prove any significant relationship
between smoking status and the occurrence of MDR-TB. How-
ever, significant associations are observed between the dura-
tion of smoking among smokers and the status of passive
smokers to the occurrence of MDR-TB. As shown in Table 4,
with an increase of 1 year of smoking, it will increase the odds
of developing MDR-TB by one unit (OR 1.08, 95% CI 1.02–1.14).
Interestingly, passive smoke is found to be a preventive factor
from developing MDR-TB in this recent study. The results of
this study suggest that those who are passive smokers have
75% less chance of developing MDR-TB compared to nonpas-
sive smokers (OR .25, 95% CI .07–.87). Yet, this study failed to
prove significant associations between nicotine dependency,
alcoholic status, and substance abuse, and the occurrence
of MDR-TB.
All the factors that are found to be significantly associated
with the occurrence of MDR-TB during the univariable analy-
sis are once again introduced in a multiple logistic-regression
model to determine the factors that independently influence
the occurrence of MDR-TB. Based on the results, the factors
that are independently associated with the occurrence ofs.
Chi squarea p Crude odds ratiob (95% CI)
4.701 .030 Ref.
2.58 (1.08–6.19)
>.950 .84 (.23–3.14)
Ref.
4.19 .041 2.44 (1.02–5.83)
Ref.
.766 .67 (.18–2.47)
Ref.
man immunodeficiency virus.
Table 3 – Treatment-related factors of cases and controls.
Cases (n = 30) Controls (n = 120) Chi squarea p Crude odds ratiob (95% CI)
n % n %
Compliance to treatmentc
Not compliant 10 33.3 12 10.0 .003 4.50 (1.71–11.82)
Compliant 20 66.7 108 90.0 Ref.
Type of caseb
Previously treated 20 66.7 22 18.3 27.81 <.001 8.91 (3.66–21.67)
New case 10 33.3 98 81.7 Ref.
Smear at diagnosisb
Positive 21 70.0 66 55.0 2.22 .140 1.91 (.81–4.51)
Negative 9 30.0 54 45.0 Ref.
Smear at 2nd monthc
Positive 10 33.3 8 6.7 <.001 7.00 (2.46–19.89)
Negative 20 66.7 112 93.3 Ref.
Smear at 6th monthc
Positive 7 23.3 2 1.7 <.001 17.96 (3.51–91.99)
Negative 23 76.7 118 98.3 Ref.
Note: Statistically significant at p < .05. CI = confidence interval.
a Pearson chi-square test was performed.
b Simple binary logistic regression was performed.
c Fisher’s exact test was performed.
Table 4 – Smoking status, alcoholic status, and history of substance abuse among cases and controls (N = 150).
Cases (n = 30) Controls (n = 120) Chi squarea p Crude odds ratio (95% CI)b
n % n %
Smoking
Current smoker 8 26.7 41 34.2 .68 .713 .72 (.29–1.83)
Former smoker 5 16.7 16 13.3 1.16 (.37–3.61)
Nonsmoker 17 56.6 63 52.5 Ref.
Duration of smoking (y)c
Median 37.00 25.00 .012 1.08 (1.02–1.14)
(IQR) (26.00; 43.50) (14.5; 35.00)
Passive smoker
Yes 3 10.0 37 30.8 5.33 .031 .25 (.07–.87)
No 27 90.0 83 69.2 Ref.
Pack years (n = 70)
More than 15 10 77.0 31 54.4 2.22 .148 2.79 (.69–11.24)
15 or less 3 23 26 45.6 Ref.
Nicotine dependency (n = 49)d
High 4 50.0 8 19.5 .067 .50 (.15–1.66)
Moderate 2 25.0 6 14.6 .33 (.07–1.65)
Low 2 25.0 27 65.9 Ref.
Alcoholic statusd
Yes 3 10.0 8 6.7 .460 1.56 (.39–6.26)
No 27 90.0 112 93.3 Ref.
Substance abused
Yes 3 10.0 16 13.3 .766 .72 (.19–2.66)
No 27 90.0 104 86.7 Ref.
Note: Statistically significant at p < .05. CI = confidence interval; IQR = interquartile range.
a Pearson chi-square test was performed.
b Simple binary logistic regression was performed.
c Mann–Whitney U test was performed.
d Fisher’s exact test was performed.
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Table 5 – Multiple logistic-regression model of factors influencing the occurrence of multidrug-resistant tuberculosis.
Characteristics p Adjusted odds ratioa 95% CI
Living in suburban areas .013 4.88 (1.39–17.04)
Is married .052 3.18 (.99–10.22)
Positive sputum smears at the 2nd month of treatment .011 6.82 (1.54–30.15)
Positive sputum smears at the 6th month of treatment .058 7.41 (.93–58.98)
Was treated previously <.001 9.48 (3.12–28.77)
CI = confidence interval.
a Adjusted for sex, occupation, ethnicity, level of education, history of incarceration, exposure to tuberculosis patients, household crowding,
compliance, smoking status, passive smokers, duration of smoking, level of nicotine dependency, alcoholic status, and substance abuse.
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17.04), positive sputum smears at the 2ndmonth of treatment
(OR 6.82, 95% CI 1.54–30.15), and were treated previously (OR
9.48, 95% CI 3.12–28.77) (Table 5).
Discussion
In this present study, the median age for the cases was found
to be 47 years old. Meanwhile, the median age for the controls
was 36 years old. A similar age range was reported in two
other previous studies conducted in eastern China and Iran
with a mean age of MDR-TB cases at 47 years old and 44 years
old, respectively [15,16]. A pooled meta-analysis study sup-
ported that MDR-TB is more common in patients under
65 years old compared to those under the age of 45 [17]. How-
ever, the findings of this study are in contrary with several
other previous studies that showed that patients with MDR-
TB are slightly younger as compared to the non-MDR-TB
patients [9,18,19]. Young people are believed to be more acces-
sible to MDR-TB because they are more mobile and busier
with work, hence have less time for treatments. Meanwhile,
MDR-TB among the older age group indicates reactivation of
past infections with resistant strains.
Sputum-smear conversion is often used as a method to
monitor the treatment response in patients with pulmonary
TB. In this current study, it was found that positive sputum
smears in the 2nd month of anti-TB treatment are one of
the predictors for the occurrence of MDR-TB. The finding is
consistent with findings from an earlier study by Hovhan-
nesyan and Breeze in 2012 [20]. Their study showed that the
time taken for conversion to negative sputum in patients
resistant to MDR-TB in Armenia is more than 2 months [20].
However, the findings of this study differ with another inde-
pendent study conducted in Iran, which tried to look at the
time to sputum-smear conversion among MDR-TB patients.
The research team found that most patients with MDR-TB
converted to negative sputum smears within 51 days of treat-
ment [21].
Many studies had successfully proven a significant associ-
ation between the past history of TB treatment and the occur-
rence of MDR-TB [17,18,22]. Patients who had been treated
with TB treatments were more likely to be resistant to anti-
TB drugs than those who never received any treatments. Sim-
ilar results were also shown in our recent study. It is said that
this group of patients acquired MDR-TB through poor compli-
ance, lack of supervision during treatment, improper drug
regimen, inadequate or irregular drug supply, and poorinfection control measures in treatment settings [23]. How-
ever, all the three latter factors were not examined in this
study. Further research on this issue in Malaysia and its rela-
tionship with the occurrence of MDR-TB is deemed necessary
in the future.
A study in Georgia demonstrated that those in cities had
43% greater MDR-TB risk compared to those in rural areas
[24]. In this recent study, a significant relationship was found
between the patients’ area of living and MDR-TB. It may occur
due to an indirect relationship with their exposure to foreign
immigrants in the community and workplace. Malaysia faces
an influx of immigrants from neighboring countries, such as
Indonesia, Myanmar, and Bangladesh, each year. As we are
aware, these countries have been classified by the World
Health Organization as countries with higher percentages of
previously treated TB cases with MDR-TB in the Southeast
Asia region as compared to Malaysia [2]. These immigrants
are mostly employed in the construction, farming, agricul-
ture, and housekeeping industries [25], and most of them live
in squatter settlements that are numerous in suburban areas.
Adherence to treatment has been considered as one of the
keys in preventing the occurrence of drug-resistant TB cases.
Every patient diagnosed with TB should adhere to the treat-
ment regime for at least 6 months, starting with 2 months
of intensive treatment and continuing with the continuation
phase of treatment for another 4 months. In this study, we
also look at the relationship between compliance and the
occurrence of MDR-TB. Our univariable analysis demon-
strated that there is a significant association between these
two. This finding is also supported by several other studies
that have been conducted previously [26–28]. However, there
are also other studies that show the opposite. It was said that
treatment failure occurs only at high rates of nonadherence
(between 60% to 80% of nonadherence). Drug resistance are
believed to occur not due to noncompliance, but due to
patient pharmacokinetic variability [29]. Conflicting findings
on the relationship between nonadherence and drug-
resistant TB might also occur due to the lack of uniformity
in how we define and measure nonadherence [30].
Another factor that was found to have a significant associ-
ation with the occurrence of MDR-TB is patients’ marital sta-
tus. In this study, it was found that patients with TB who are
single are three times more likely to become MDR-TB than
those who are married. Single people are believed to be more
vulnerable to anti-TB drug resistance because of the lack of
moral support that comes from couples and families where
the support factor has been shown to play a role in
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treatments [31]. Moreover, those who are single are more
vulnerable to engage in high-risk behaviors, such as drug
abuse, smoking, HIV infections, and alcohol consumption,
which also have an impact on treatment compliance [32].
Diabetes was found to be significantly associated with
MDR-TB in our study’s univariable analysis. This is in line
with other previous studies that showed that diabetic
patients were 2.0–2.6 times more likely to be MDR-TB com-
pared to nondiabetics [11,33]. In some other studies, the asso-
ciation between these two factors was only seen in new TB
cases, but not in previously treated patients [34,35]. There is
no direct explanation on how diabetes could affect drug-
resistant TB. Previous researchers had tried to find a correla-
tion between these two issues by looking at the corner of
genetic differences and at the interference of hyperglycemic
states on anti-TB drug absorption [36,37].
Our study has a few limitations. First, this recent study
was only conducted in one government treatment center
and does not include patients who go to private health-care
facilities. Therefore, we cannot generalize the findings to
the other treatment settings in other parts of Malaysia. Sec-
ond, the data on Mycobacterium tuberculosis strain variability
were not included in this study. This factor has been found
to be associated with the transmission of MDR-TB in other
previousmicrobiological studies. However, this study has suc-
cessfully contributed new ideas about the background and
the factors that influence the occurrence of MDR-TB among
local TB patients. In return, it helps in better planning of
MDR-TB case detection and management of these patients.
Conclusions
In conclusion, this study has found that those previously trea-
ted patients, have positive sputum smears at the 2nd month
of treatment, and living in suburban areas are at higher odds
of developing MDR-TB. Therefore, greater emphasis should be
given to patients with these characteristics in order to facili-
tate improvements in early case detection, and thus, better
treatment can be given.
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